CN113207290B - 具有改善的特性的活性化合物产品、其制备和制剂 - Google Patents

具有改善的特性的活性化合物产品、其制备和制剂 Download PDF

Info

Publication number
CN113207290B
CN113207290B CN201980082044.4A CN201980082044A CN113207290B CN 113207290 B CN113207290 B CN 113207290B CN 201980082044 A CN201980082044 A CN 201980082044A CN 113207290 B CN113207290 B CN 113207290B
Authority
CN
China
Prior art keywords
active compound
formula
wetting agent
compound product
acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980082044.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113207290A (zh
Inventor
P·费伊
M·佐瓦
J·布罗考伯
M·隆格里希
G·贝克
H·纽曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN113207290A publication Critical patent/CN113207290A/zh
Application granted granted Critical
Publication of CN113207290B publication Critical patent/CN113207290B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980082044.4A 2018-12-17 2019-12-16 具有改善的特性的活性化合物产品、其制备和制剂 Active CN113207290B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18213115 2018-12-17
EP18213115.1 2018-12-17
PCT/EP2019/085255 WO2020126983A1 (en) 2018-12-17 2019-12-16 Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof

Publications (2)

Publication Number Publication Date
CN113207290A CN113207290A (zh) 2021-08-03
CN113207290B true CN113207290B (zh) 2024-04-09

Family

ID=64744472

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980082044.4A Active CN113207290B (zh) 2018-12-17 2019-12-16 具有改善的特性的活性化合物产品、其制备和制剂

Country Status (19)

Country Link
US (1) US12172996B2 (https=)
EP (1) EP3898624A1 (https=)
JP (1) JP7529667B2 (https=)
KR (1) KR102872983B1 (https=)
CN (1) CN113207290B (https=)
AR (1) AR116912A1 (https=)
AU (1) AU2019409269B2 (https=)
BR (1) BR112021009122A2 (https=)
CA (1) CA3123360A1 (https=)
CL (1) CL2021001580A1 (https=)
CO (1) CO2021007668A2 (https=)
IL (1) IL283976B2 (https=)
JO (1) JOP20210155B1 (https=)
MX (1) MX2021007090A (https=)
PE (1) PE20211593A1 (https=)
SG (1) SG11202104953VA (https=)
TW (1) TWI830835B (https=)
UA (1) UA129677C2 (https=)
WO (1) WO2020126983A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI830835B (zh) 2018-12-17 2024-02-01 德商亞德維瑞醫藥有限公司 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物
EP4099987B1 (en) 2020-02-03 2025-03-12 Adverio Pharma GmbH Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
EP3925953A1 (en) 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
WO2025114276A1 (en) 2023-12-01 2025-06-05 Krka, D.D., Novo Mesto Solid oral composition comprising vericiguat

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013076168A1 (de) * 2011-11-25 2013-05-30 Bayer Pharma Aktiengesellschaft Verfahren zur herstellung von substituierten 5-fluor-1h-pyrazolopyridinen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2745813B1 (fr) 1996-03-07 1998-05-07 Rhone Poulenc Chimie Agglomerats spheriques d'acide 10-phenothiazinylpropanoique et leur procede de preparation
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
PL2604608T3 (pl) 2009-11-27 2016-02-29 Adverio Pharma Gmbh Sposób wytwarzania {4,6-diamino-2-[1-(2-fluorobenzylo)-1H-pirazolo[3,4-b]pirydyn-3-ylo]pirymidyn-5-ylo}metylokarbaminianu metylu
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
MX2015010725A (es) * 2013-02-21 2016-05-31 Adverio Pharma Gmbh Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato.
PL2792682T3 (pl) 2013-04-19 2017-04-28 Zach System Sposób wytwarzania stałej postaci octanu abirateronu
WO2016113415A1 (en) * 2015-01-16 2016-07-21 Sandoz Ag Process for the preparation of riociguat essentially free from genotoxic impurities
WO2017025981A1 (en) * 2015-08-13 2017-02-16 Msn Laboratories Private Limited Process for the preparation of methyl 4,6-diamino-2-[l-(2-fhiorobenzvr)-lh-pyrazolo i3,4-blpvridin-3-vn-5-pyrimidinyl(methvl)carbamate and its polymorphs thereof
TWI830835B (zh) 2018-12-17 2024-02-01 德商亞德維瑞醫藥有限公司 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物
CN113272286B (zh) 2019-01-22 2024-04-16 阿德弗里奥药品有限责任公司 制备4-(2,2,3,3-四氟丙基)吗啉的方法
EP4099987B1 (en) * 2020-02-03 2025-03-12 Adverio Pharma GmbH Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
EP3925953A1 (en) * 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013076168A1 (de) * 2011-11-25 2013-05-30 Bayer Pharma Aktiengesellschaft Verfahren zur herstellung von substituierten 5-fluor-1h-pyrazolopyridinen

Also Published As

Publication number Publication date
MX2021007090A (es) 2021-08-11
PE20211593A1 (es) 2021-08-18
CL2021001580A1 (es) 2021-12-03
SG11202104953VA (en) 2021-06-29
JOP20210155B1 (ar) 2025-10-01
AU2019409269A1 (en) 2021-06-03
JP7529667B2 (ja) 2024-08-06
IL283976B1 (en) 2024-12-01
TW202039488A (zh) 2020-11-01
IL283976B2 (en) 2025-04-01
CN113207290A (zh) 2021-08-03
JOP20210155A1 (ar) 2023-01-30
EP3898624A1 (en) 2021-10-27
KR102872983B1 (ko) 2025-10-17
BR112021009122A2 (pt) 2021-08-10
US20220048907A1 (en) 2022-02-17
UA129677C2 (uk) 2025-07-02
WO2020126983A1 (en) 2020-06-25
IL283976A (en) 2021-07-29
CA3123360A1 (en) 2020-06-25
JP2022515376A (ja) 2022-02-18
AR116912A1 (es) 2021-06-23
AU2019409269B2 (en) 2025-04-03
TWI830835B (zh) 2024-02-01
CO2021007668A2 (es) 2021-07-19
KR20210104703A (ko) 2021-08-25
US12172996B2 (en) 2024-12-24

Similar Documents

Publication Publication Date Title
CN113207290B (zh) 具有改善的特性的活性化合物产品、其制备和制剂
US11911511B2 (en) Anticancer compositions
CN102112113B (zh) 活性物质的结晶微粒，产生该活性物质的结晶微粒的方法及其在医药中的使用
CA3032233C (en) Pharmaceutical compositions comprising akt protein kinase inhibitors
KR102676383B1 (ko) 결정성 의약품의 제조
EP2714676B1 (en) A process for the preparation of polymorphic form i of etoricoxib
HK40050973A (en) Active compound product having improved properties, production and formulation thereof
RU2818488C2 (ru) Продукт активного соединения метил { 4,6-диамино-2-[5-фтор-1-(2-фторбензил)-1H-пиразоло[3,4-b]пиридин-3-ил]пиримидин-5-ил} карбамата, имеющий улучшенные свойства, его получение и состав
JP4498679B2 (ja) 結晶性イソキサゾール誘導体およびその医薬製剤
HK40050973B (zh) 具有改善的特性的活性化合物产品、其制备和制剂
TWI904746B (zh) 具有改良溶解度之新穎瓦莫洛龍(vamorolone)製劑
HK40066972A (en) Anticancer compositions
TW202229267A (zh) 再加工方法
HK1090287A (en) Process for production of crystals of a medicinally effective ingredient, crystals obtained thereby and their use in pharmaceutical preparations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40050973

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant